Products containing the blood pressure drug valsartan, withdrawn from the U.S. and European markets because some lots were tainted with possible carcinogens, are not associated with a markedly increased short term risk of cancer, according to an expedited analysis.
The findings were published in The BMJ.
At the same time, the authors say further studies are required to evaluate the risks for longer-term effects and for specific types of cancer. Their study was published before the discovery of a second impurity in the recalled lots of valsartan.
In July 2018, some valsartan products manufactured by the Chinese company Zhejiang Huahai Pharmaceuticals were suspected of having been contaminated with N-nitrosodimethylamine (NDMA), an impurity that can cause cancer.